Yes

Antiparasitic Agent, Topical; Pediculocide; Scabicidal Agent

Treatment of scabies ( Sarcoptes scabiei), Pediculus capitis (head lice), and Pediculus pubis (crab lice); FDA recommends reserving lindane as a second-line agent or with inadequate response to other therapies

B

Clinical effects on the fetus: There are no well controlled studies in pregnant women; treat no more than twice during a pregnancy

Hypersensitivity to lindane or any component; premature neonates; acutely inflamed skin or raw, weeping surfaces

Not considered a drug of first choice; use with caution in infants and small children, and patients with a history of seizures; avoid contact with face, eyes, mucous membranes, and urethral meatus. Because of the potential for systemic absorption and CNS side effects, lindane should be used with caution; consider permethrin or crotamiton agent first.

<1%: Cardiac arrhythmia, dizziness, restlessness, seizures, headache, ataxia, eczematous eruptions, contact dermatitis, skin and adipose tissue may act as repositories, nausea, vomiting, aplastic anemia, hepatitis, burning and stinging, hematuria, pulmonary edema

Symptoms of overdose include vomiting, restlessness, ataxia, seizures, arrhythmias, pulmonary edema, hematuria, hepatitis. Absorbed through skin and mucous membranes and GI tract, has occasionally caused serious CNS, hepatic and renal toxicity when used excessively for prolonged periods, or when accidental ingestion has occurred

If ingested, perform gastric lavage and general supportive measures; diazepam 0.01 mg/kg can be used to control seizures.

Increased toxicity: Oil-based hair dressing may increase toxic potential

Directly absorbed by parasites and ova through the exoskeleton; stimulates the nervous system resulting in seizures and death of parasitic arthropods

Absorption: Systemic absorption of up to 13% may occur

Distribution: Stored in body fat and accumulates in brain; skin and adipose tissue may act as repositories

Metabolism: By the liver

Half-life: Children: 17-22 hours

Time to peak serum concentration: Topical: Children: 6 hours

Elimination: In urine and feces

Children and Adults: Topical:

Pediculosis, capitis and pubis: 15-30 mL of shampoo is applied and lathered for 4-5 minutes; rinse hair thoroughly and comb with a fine tooth comb to remove nits; repeat treatment in 7 days if lice or nits are still present

May cause dizziness or restlessness

May cause aplastic anemia; use caution with clozapine and carbamazepine

No information available to require special precautions

No effects or complications reported

For external use only. Do not apply to face and avoid getting in eyes. Do not apply immediately after hot soapy bath. Apply from neck to toes. Bathe to remove drug after 8-12 hours. Repeat in 7 days if lice or nits are still present. Clothing and bedding must be washed in hot water or dry cleaned to kill nits. Wash combs and brushes with lindane shampoo and thoroughly rinse. May need to treat all members of household and all sexual contacts concurrently. Report if condition persists or infection occurs.

Lindane lotion should be applied to dry, cool skin

Cream: 1% (60 g, 454 g)

Lotion: 1% (60 mL, 473 mL, 4000 mL)

Shampoo: 1% (60 mL, 473 mL, 4000 mL)

Davies JE, Dedhia HV, Morgade C, et al, "Lindane Poisonings," Arch Dermatol, 1983, 119(2):142-4.

Eichenfield LF, Honig PJ, "Blistering Disorders in Childhood," Pediatr Clin North Am, 1991, 38(4):959-76.

Hogan DJ, Schachner L, Tanglertsampan C, "Diagnosis and Treatment of Childhood Scabies and Pediculosis," Pediatr Clin North Am, 1991, 38(4):941-57.

Kurt TL, Bost R, Gilliland M, et al, "Accidental Kwell® (Lindane) Ingestions," Vet Hum Toxicol, 1986, 28(6):569-71.

Liu LX and Weller PF, "Antiparasitic Drugs," N Engl J Med, 1996, 334(18):1178-84.

Pramanik AK and Hansen RC, "Transcutaneous Gamma Benzene Hexachloride Absorption and Toxicity in Infants and Children," Arch Dermatol, 1979, 115(10):1224-5.

Solomon BA, Haut SR, Carr EM, et al, "Neurotoxic Reaction to Lindane in an HIV-Sero Positive Patient, An Old Medication's New Problem," J Fam Pract, 1995, 40(3):291-5-6.